Evonetix
Evonetix is a biotechnology company that develops a synthetic biology platform for DNA synthesis and gene assembly. The company's proprietary technology uses silicon arrays manufactured through semiconductor microfabrication, enabling various miniaturized reaction sites for parallel DNA synthesis. The platform is designed to synthesize genes with high GC content and assemble long DNA sequences with high fidelity.…
Funding snapshot
About
Evonetix is a biotechnology company that develops a synthetic biology platform for DNA synthesis and gene assembly. The company's proprietary technology uses silicon arrays manufactured through semiconductor microfabrication, enabling various miniaturized reaction sites for parallel DNA synthesis. The platform is designed to synthesize genes with high GC content and assemble long DNA sequences with high fidelity. Evonetix's approach integrates thermal control of individual reaction sites on the silicon array, allowing precise control over DNA synthesis chemistry and enabling error correction during the assembly process. The technology aims to democratize gene synthesis for applications in drug discovery, vaccine development, agricultural biotechnology, and industrial biotechnology. Founded in 2015 and headquartered in Saffron Walden, United Kingdom, Evonetix has raised approximately $70 million in Series B funding from investors including DCVC, Draper Esprit, Cambridge Consultants, Rising Tide Fund, Civilization Ventures, Morningside, Foresite Capital, Providence Equity Partners, Molten Ventures, and Providence Investment Company.
Business model
Genomics > Applied Genomics > Synthetic Biology,
Life Sciences Platforms and Tools > Research Services > Diversified
Team background
College Wise > London Business School (LBS)
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.